New Study “Antibody-Drug Conjugates 2011” Now Available at MarketPublishers.com

29 Sep 2011 • by Natalie Aster
New Study “Antibody-Drug Conjugates 2011” Now Available at MarketPublishers.com

LONDON – The stakeholders in the field of ADC have shown true interest and enthusiasm about the recent approval of Seattle Genetics’ antibody-drug conjugate Adcetris. Rising approval had its grounds in stunning tumor response rates in relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. Healthy and large-scale sales rates of the expensive therapy are expected by the specialists. However, the FDA request post-approval studies indicating that the high response rates translate into improved survival rate.

New market research reportAntibody-Drug Conjugates 2011worked out by La Merie provides a compilation of data and information about antibody-drug conjugate companies, technologies and products in R&D. An all-covering analysis of the state of the art and key trends is featured along with detailed appraisal of the clinical results of active and discontinued ADC projects and products. Key stakeholders and their contribution to the growth ADC technology and products is reviewed.

Report Details:

Title: Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
Published: September, 2011
Pages: 274
Price: US$ 2,632

Report Contents:

1. ABBREVIATIONS

2. OVERVIEW

3. EXECUTIVE SUMMARY

4. DRUGS AND LINKERS USED IN ANTIBODY-DRUG CONJUGATES

5. ANTIBODIES USED IN ANTIBODY-DRUG CONJUGATES

6. ANALYSIS OF STAKEHOLDERS IN ANTIBODY-DRUG CONJUGATES

7. CLINICAL VALUE OF ANTIBODY-DRUG CONJUGATES

8. R&D PIPELINE ANALYSIS OF ANTIBODY-DRUG CONJUGATES

9. COMMERCIAL VALUES OF ANTIBODY-DRUG CONJUGATES

10. COMPANY PROFILES
Abbott
Aeterna Zentaris

Allozyne
Alpha Cancer Technologies
Ambrx
Amgen
Amunix
Anaphore
Astellas Pharma (Agensys)
AstraZeneca (MedImmune)
Bayer Healthcare Pharmaceuticals
Biogen Idec
Biotest
Bristol-Myers Squibb (Medarex)
Celldex Therapeutics
Centrose
Daiichi Sankyo
Genmab
GlaxoSmithKline
ImmunoGen

More new market reports by the publisher can be found at La Merie page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com